Adding Trulicity to SGLT2 inhibitors lowers blood sugar levels, shows AWARD-10 data

Type 2 diabetes patients whose blood sugar levels were not adequately controlled on SGLT-2 inhibitor therapy and metformin showed an improvement in average blood sugar concentration over two to three months (A1C) when Eli Lilly's (NYSE: LLY) Trulicity (dulaglutide) was added in a Phase IIIb study.

New data from the AWARD-10 study reflects that the addition of Trulicity brought a clinically meaningful and statistically significant improvement in A1C at both doses that were studied.

A statement provided by Lilly on this data read: "These results are positive for Trulicity, as they provide new information that Trulicity in combination with an SGLT-2 inhibitor may be effective and well tolerated in people with type 2 diabetes. They also show that Trulicity works effectively with all approved SGLT-2 inhibitors, as the study tested Trulicity in combination with all three available SGLT-2 inhibitors."